According to tissue microarray (TMA) data, patients classified with stage II PCa (localized tumor with medium to low PSA levels) had comparable SKP2:FOXA1 ratios to normal prostate, indicating similar protein levels and no significant differences in abundance. The gene discussed is SKP2; the disease is posterior cortical atrophy.